Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Cardiol Therapeutics Inc.

    NASDAQ: CRDL · Real-Time Price · USD
    1.25
    0.00 (0.00%)
    At close: Jun 02, 2025, 2:13 PM
    0.00%
    Bid 0.91
    Market Cap 103.31M
    Revenue (ttm) n/a
    Net Income (ttm) -36.68M
    EPS (ttm) -0.34
    PE Ratio (ttm) -3.68
    Forward PE -2.5
    Analyst Buy
    Ask 1.54
    Volume 217,923
    Avg. Volume (20D) 192,819
    Open 1.23
    Previous Close 1.25
    Day's Range 1.18 - 1.28
    52-Week Range 0.77 - 3.12
    Beta 0.66

    About CRDL

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol CRDL
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for CRDL stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Why Price Moved

    Why Price Moved is a one-sentence explanation of why a stock is moving higher or down. By removing noise and collecting signals from news, press releases and SEC filings, we can pinpoint the trigger for price movements.
    7 months ago
    -6.63%
    Cardiol Therapeutics shares are trading lower afte... Unlock content with Pro Subscription
    7 months ago
    +3.7%
    Cardiol Therapeutics shares are trading lower after the company announced a preliminary prospectus for a proposed public offering of common stock, size or amount not disclosed.
    news image

    3 days ago · newsfilecorp.com

    Cardiol Therapeutics Reports Results of 2025 Annual General Meeting of Shareholders

    Toronto, Ontario--(Newsfile Corp. - May 29, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing anti...

    news image

    5 days ago · newsfilecorp.com

    Cardiol Therapeutics to Webcast Virtual Annual General Meeting of Shareholders on May 28th at 4:30 p.m. EDT

    Toronto, Ontario--(Newsfile Corp. - May 27, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing anti...

    news image

    1 month ago · newsfilecorp.com

    Cardiol Therapeutics Nominates Dr. Timothy Garnett to Its Board of Directors

    Former Chief Medical Officer of Eli Lilly brings more than thirty years of pharmaceutical industry experience Toronto, Ontario--(Newsfile Corp. - April 29, 2025) - Cardiol Therapeutics Inc. (NASDAQ: C...

    news image

    1 month ago · zacks.com

    Cardiol Therapeutics Stock: Is Cannabis Potential Priced In?

    Cardiol Therapeutics shows promise with its CBD-based heart therapy, but a lack of approved drugs and a narrow pipeline raise red flags for cautious investors.

    news image

    1 month ago · newsfilecorp.com

    Cardiol Therapeutics Enrolls First Patient in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis

    Designed to assess the impact of CardiolRx™ on preventing episodes of recurrent pericarditis, the first patient has been randomized by Northwestern University in Chicago. Based on a successful end-of-...

    news image

    2 months ago · newsfilecorp.com

    Cardiol Therapeutics Announces Year-End 2024 Update on Operations

    Reported positive data from the Phase II MAvERIC-Pilot study investigating the impact of CardiolRx™ administered to patients with symptomatic recurrent pericarditis; results support advancing to the P...

    news image

    3 months ago · newsfilecorp.com

    Cardiol Therapeutics to Present at TD Cowen 45th Annual Health Care Conference

    Toronto, Ontario--(Newsfile Corp. - March 3, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing ant...

    Add to Watchlist